An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients.
about
BRCAness: finding the Achilles heel in ovarian cancerProteomics of mouse BRCA1-deficient mammary tumors identifies DNA repair proteins with potential diagnostic and prognostic value in human breast cancerCytotoxic and targeted therapy for hereditary cancersGenomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancersBreast cancer classification and prognostication through diverse systems along with recent emerging findings in this respect; the dawn of new perspectives in the clinical applications.Predictive biomarkers for triple negative breast cancer treated with platinum-based chemotherapy.Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapyAssessing the function of homologous recombination DNA repair in malignant pleural effusion (MPE) samples.Lack of genomic heterogeneity at high-resolution aCGH between primary breast cancers and their paired lymph node metastasesIdentification by array comparative genomic hybridization of a new amplicon on chromosome 17q highly recurrent in BRCA1 mutated triple negative breast cancer.Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations.Regulators of homologous recombination repair as novel targets for cancer treatment.Drug therapy for hereditary cancersIn Vitro Enhanced Sensitivity to Cisplatin in D67Y BRCA1 RING Domain Protein.Microarrays in the 2010s: the contribution of microarray-based gene expression profiling to breast cancer classification, prognostication and prediction.Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105Quantitative copy number analysis by Multiplex Ligation-dependent Probe Amplification (MLPA) of BRCA1-associated breast cancer regions identifies BRCAness.Genomic Complexity Profiling Reveals That HORMAD1 Overexpression Contributes to Homologous Recombination Deficiency in Triple-Negative Breast Cancers.Identification of BRCA1 Deficiency Using Multi-Analyte Estimation of BRCA1 and Its Repressors in FFPE Tumor Samples from Patients with Triple Negative Breast Cancer.Next generation sequencing of triple negative breast cancer to find predictors for chemotherapy response.Identification of BRCA1-like triple-negative breast cancers by quantitative multiplex-ligation-dependent probe amplification (MLPA) analysis of BRCA1-associated chromosomal regions: a validation study.BRCAness as a Biomarker for Predicting Prognosis and Response to Anthracycline-Based Adjuvant Chemotherapy for Patients with Triple-Negative Breast CancerImpact of intertumoral heterogeneity on predicting chemotherapy response of BRCA1-deficient mammary tumors.Proteomics of genetically engineered mouse mammary tumors identifies fatty acid metabolism members as potential predictive markers for cisplatin resistance.Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers.Differential chemotherapeutic sensitivity for breast tumors with "BRCAness": a review.BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1Innovations that reach the patient: early health technology assessment and improving the chances of coverage and implementation.Long-term survival of advanced triple-negative breast cancers with a dose-intense cyclophosphamide/anthracycline neoadjuvant regimen.Triple-negative breast cancer: bridging the gap from cancer genomics to predictive biomarkers.Understanding the biology of triple-negative breast cancer.Opportunities and hurdles in the treatment of BRCA1-related breast cancer.Advances in the approach to novel drug clinical development for breast cancer.BRCA1-like profile is not significantly associated with survival benefit of non-myeloablative intensified chemotherapy in the GAIN randomized controlled trial.Genetic Dissection of Cancer Development, Therapy Response, and Resistance in Mouse Models of Breast Cancer.Therapeutic targeting and patient selection for cancers with homologous recombination defects.Mutational Signatures in Breast Cancer: The Problem at the DNA LevelBiological Subtypes of Triple-Negative Breast Cancer.Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies.Copy number profiling by array comparative genomic hybridization identifies frequently occurring BRCA2-like male breast cancer.
P2860
Q24630872-B87468CB-3197-4218-A999-C53E4573F431Q24632628-A1148DFB-1F6D-4F53-816A-95B3CB3F9351Q26739366-564D5D99-D81E-4E02-B71D-E645E0CCB9B8Q27006938-F80328B9-886A-4140-A051-C98EC3792B60Q30245184-324F2415-9734-4998-B3AF-F1D2874337EFQ33441772-FFB4DFE2-8A31-41C4-91BC-DBB565CD0E7CQ33827045-C46FCD51-167A-4291-AA83-57B41F67F2A0Q33877435-771C01D6-9695-497E-BDAF-251D77EB96A2Q33988970-FF4492C9-C080-45E1-9473-73F100E58927Q35000673-6A972362-8A69-42F6-85B8-5479127227ADQ35051154-31AEEAC7-2CB4-449A-AC6E-CF6E69CB56D6Q35200273-C133E6C9-6C9E-412A-9373-32F80143CD10Q35208929-B098BB86-CCE5-4B9F-BC86-1FE186E2C631Q35440379-15A67AD3-12A4-4D0F-B004-07AFF5B18EFEQ35558070-B41C18D5-73A6-4277-A71E-D0B11811FEA4Q35671356-02A24803-E35F-4ED6-8E2A-30726F5E3C4AQ35683623-F737D369-0109-41EF-A22F-A7E23A71D8D9Q35812762-53864E23-C6C4-40D4-A4E2-36F9B2DAD4B0Q35989438-C1D831CC-4BB2-47F9-97AE-4D4687610ECEQ36119077-B8B465A0-161D-4CF3-98DA-14D81B01860DQ36166929-36529BBA-F77B-41A8-9DF3-00ADDC46875CQ36224769-F2FB5F23-BF75-460F-86EE-6DF0C55EEB3DQ36456104-F1AFDF0A-BE09-422A-9650-EC9E9C2325E0Q36832502-C46451CF-932A-4D24-A408-32BFBB71B09EQ36896061-46F146B5-E8C0-4C4F-A96F-F21E3577A168Q37128739-9FB6E0AB-1A85-46DC-8489-D31361ED1F02Q37137914-A579EBFC-8F46-43EE-934B-C40703339EE5Q37404683-5C836B5B-F39F-4730-A18D-CE1E135285ECQ37650748-105938E6-D18E-4533-9AE1-73E7171F85D2Q37704344-B99DFCF9-ED73-4E89-A602-AE3A439439EAQ38046574-FC7DB135-F2F1-49D5-AD99-3BF6BA0F98F0Q38129725-ADA50146-9F22-43DD-9C31-B735790BF01DQ38206546-B2016486-54EA-40DD-BC42-5A948D78E545Q38617840-5797B4B8-84BF-4B7A-B819-C2B06535DD78Q38798405-886747E5-BC9A-4786-9A81-4C13C7AE83D4Q39251572-3B86DF38-B478-4290-AAAA-A2EE1FB586E9Q39345007-6A5CC08C-1AEB-45A9-8A01-FB928DFBE633Q39370768-1320409C-CDBA-40CC-9977-E5FC747FF0DFQ39375196-CF0C7E64-383A-4188-BF8C-4E1DC6BE8057Q40556065-31FCF487-365C-43BC-8D71-FE9483477E9F
P2860
An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients.
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
An aCGH classifier derived fro ...... gative breast cancer patients.
@ast
An aCGH classifier derived fro ...... gative breast cancer patients.
@en
type
label
An aCGH classifier derived fro ...... gative breast cancer patients.
@ast
An aCGH classifier derived fro ...... gative breast cancer patients.
@en
prefLabel
An aCGH classifier derived fro ...... gative breast cancer patients.
@ast
An aCGH classifier derived fro ...... gative breast cancer patients.
@en
P2093
P2860
P356
P1433
P1476
An aCGH classifier derived fro ...... gative breast cancer patients.
@en
P2093
E G E de Vries
E H van Beers
F E Froklage
H van Tinteren
J G Schrama
J Wesseling
L F A Wessels
M A Vollebergh
M Holtkamp
P2860
P304
P356
10.1093/ANNONC/MDQ624
P577
2010-12-06T00:00:00Z